Particle.news
Download on the App Store
8 ARTICLES
·
last wk.

BioMarin to Acquire Amicus for $4.8 Billion in Cash

The takeover expands BioMarin’s rare-disease portfolio with immediate revenue from two marketed therapies.

**HANDOUT** Amicus Therapeutics
**HANDOUT**SINGLE USE** Alexander Hardy, CEO of BioMarin.
Image
Image

Overview

  • BioMarin will pay $14.50 per share in an all-cash deal valued at $4.8 billion, unanimously approved by both companies’ boards.
  • The purchase adds Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for late-onset Pompe, along with Phase 3 FSGS candidate DMX-200.
  • Amicus reported roughly $599 million in combined net sales from Galafold and Pombiliti + Opfolda over the past four quarters.
  • Amicus resolved Galafold patent disputes with Aurobindo and Lupin, pushing expected U.S. generic entry to early 2037.
  • BioMarin plans to fund the deal with cash and $3.7 billion of non-convertible debt, projects non-GAAP EPS accretion within 12 months and leverage below 2.5x within two years, and targets a Q2 2026 close pending approvals as shares of both companies jumped on the news.